NCT02252146View on ClinicalTrials.gov

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

IMO-8400

MO-8400 given subcutaneously twice weekly

Trial Locations (12)

10019

Columbia University Medical Center, New York

30306

Emory University, Atlanta

37232

Vanderbilt Ingram Cancer Center, Nashville

44109

Cleveland Clinic, Cleveland

47905

Horizon Bio Advance, Lafayette

55905

Mayo Clinic, Rochester

62526

Cancer Care Specialists of Illinois, Decatur

63110

Washington University, St Louis

77030

MD Anderson Cancer Center, Houston

90095

UCLA Medical Center, Los Angeles

02215

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Idera Pharmaceuticals, Inc.

INDUSTRY

NCT02252146 - Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation | Biotech Hunter | Biotech Hunter